RESEARCH ARTICLE
Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study Masayoshi Takahashi1, Shingo Nishida2,3, Masaki Nakamura1,2, Mina Kobayashi2, Kentaro Matsui2,4, Eiki Ito1,2, Akira Usui2, Yuichi Inoue1,2*
a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
1 Department of Somnology, Tokyo Medical University, Tokyo, Japan, 2 Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan, 3 Maezawa Hospital, Tochigi, Japan, 4 Department of Psychiatry, Tokyo Women’s Medical University, Tokyo, Japan * [email protected]
Abstract OPEN ACCESS Citation: Takahashi M, Nishida S, Nakamura M, Kobayashi M, Matsui K, Ito E, et al. (2017) Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study. PLoS ONE 12 (3): e0173535. doi:10.1371/journal.pone.0173535 Editor: Andrea Romigi, University of Rome Tor Vergata, ITALY Received: November 18, 2016 Accepted: February 21, 2017 Published: March 6, 2017 Copyright: © 2017 Takahashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To investigate the rate of and risk factors for restless legs syndrome (RLS) augmentation in Japanese patients receiving pramipexole (PPX) treatment. Records of 231 consecutive patients with idiopathic RLS who received PPX therapy for more than one month in a single sleep disorder center were analyzed retrospectively. Augmentation was diagnosed based on the Max Planck Institute criteria; associated factors were identified by logistic regression analysis. Mean age at PPX initiation was 60.6 ± 14.9 years and mean treatment duration was 48.5 ± 26.4 months. Augmentation was diagnosed in 21 patients (9.1%). Daily PPX dose and treatment duration were significantly associated with augmentation. By analyzing the receiver operating characteristic curve, a PPX dose of 0.375 mg/day was found to be the optimal cut-off value for predicting augmentation. After stratifying patients according to PPX treatment duration, at median treatment duration of 46 months, optimal cut-off values for daily doses were 0.375 and 0.500 mg/day for
Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study Masayoshi Takahashi1, Shingo Nishida2,3, Masaki Nakamura1,2, Mina Kobayashi2, Kentaro Matsui2,4, Eiki Ito1,2, Akira Usui2, Yuichi Inoue1,2*
a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
1 Department of Somnology, Tokyo Medical University, Tokyo, Japan, 2 Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan, 3 Maezawa Hospital, Tochigi, Japan, 4 Department of Psychiatry, Tokyo Women’s Medical University, Tokyo, Japan * [email protected]
Abstract OPEN ACCESS Citation: Takahashi M, Nishida S, Nakamura M, Kobayashi M, Matsui K, Ito E, et al. (2017) Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study. PLoS ONE 12 (3): e0173535. doi:10.1371/journal.pone.0173535 Editor: Andrea Romigi, University of Rome Tor Vergata, ITALY Received: November 18, 2016 Accepted: February 21, 2017 Published: March 6, 2017 Copyright: © 2017 Takahashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To investigate the rate of and risk factors for restless legs syndrome (RLS) augmentation in Japanese patients receiving pramipexole (PPX) treatment. Records of 231 consecutive patients with idiopathic RLS who received PPX therapy for more than one month in a single sleep disorder center were analyzed retrospectively. Augmentation was diagnosed based on the Max Planck Institute criteria; associated factors were identified by logistic regression analysis. Mean age at PPX initiation was 60.6 ± 14.9 years and mean treatment duration was 48.5 ± 26.4 months. Augmentation was diagnosed in 21 patients (9.1%). Daily PPX dose and treatment duration were significantly associated with augmentation. By analyzing the receiver operating characteristic curve, a PPX dose of 0.375 mg/day was found to be the optimal cut-off value for predicting augmentation. After stratifying patients according to PPX treatment duration, at median treatment duration of 46 months, optimal cut-off values for daily doses were 0.375 and 0.500 mg/day for
